IndiaThe Maharashtra Food and Drug Administration (FDA) revoked its decision to cancel the drug sale license of Cipla Pharma's Pune unit after the Bombay High Court criticized the regulatory body for acting 'overboard' and 'high-handed.' The FDA had initially canceled the license due to irregularities in the handling of Reactin Plus Tablets. Cipla challenged the order, arguing that the FDA's actions violated the principles of natural justice by conducting a hearing on a public holiday without allowing the company to present its case. The court ruled in favor of Cipla, ordering the FDA to issue a new show cause notice and reconsider its decision. The court emphasized the need for fairness and transparency in administrative procedures.
Bias read (Progressive): The article frames the FDA's actions as overly strict and lacking procedural fairness, aligning with a critique of bureaucratic overreach often associated with left-leaning perspectives. The court's emphasis on natural justice and transparency suggests a judicial approach that prioritizes individual
Why factuality (90): This article accurately describes the Bombay High Court's reprimand of the FDA regarding the cancellation of Cipla's license. It provides specific dates, the names of the judges, and the nature of the court's criticism. While slightly less detailed than some others, it aligns with the cross-source c
Why objectivity (85): The article uses phrases like 'going overboard' and 'high-handed' which may imply a slight negative tone towards the FDA. However, these terms are attributed to the court's statements rather than the author's personal opinion, maintaining a relatively balanced perspective.
